BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Unfortunately, failure to respond to imatinib developed in some CML patients as a result of resistant mutations arising in the BCR-ABL kinase domain (KD), leading to shortened survivals of CML patients with these mutations as contrasted to those without [6-11].